{"gene":"PHF5A","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2017,"finding":"PHF5A, a component of the SF3b subcomplex, is targeted by splicing modulators pladienolide, herboxidiene, and spliceostatin. Mutations in PHF5A-Y36, SF3B1-K1071, SF3B1-R1074, and SF3B1-V1078 confer resistance to these modulators, indicating a common interaction site. Crystal structure of human PHF5A shows Y36 is located on a highly conserved surface, and cryo-EM analysis of the spliceosome Bact complex shows the resistance mutations cluster in a pocket surrounding the branch point adenosine, suggesting competitive binding. PHF5A-Y36C has minimal effect on basal splicing but inhibits the global action of these splicing modulators and alters their induced intron-retention/exon-skipping profile correlating with GC content of adjacent introns and exons.","method":"Crystal structure determination, cryo-EM spliceosome analysis, mutagenesis resistance studies, RNA-seq analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure, cryo-EM, mutagenesis, and functional RNA-seq in a single study","pmids":["28541300"],"is_preprint":false},{"year":2013,"finding":"PHF5A facilitates recognition of exons with unusual C-rich 3' splice sites in thousands of essential genes in glioblastoma stem cells (GSCs). PHF5A knockdown in GSCs inhibits splicing of these genes, leading to cell cycle arrest and loss of viability, while having minimal effect in untransformed neural stem cells, astrocytes, or fibroblasts. Pharmacologic inhibition of U2 snRNP activity phenocopied PHF5A knockdown. PHF5A inhibition also compromised GSC tumor formation in vivo and inhibited growth of established GBM patient-derived xenograft tumors.","method":"Genome-wide RNAi screen, RNA-seq, pharmacologic inhibition, in vivo xenograft experiments","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genome-wide screen, mechanistic RNA-seq, in vivo validation with clean KD phenotype","pmids":["23651857"],"is_preprint":false},{"year":2016,"finding":"Phf5a is essential for maintaining pluripotency in embryonic stem cells (ESCs); depletion leads to differentiation. Mechanistically, Phf5a stabilizes the Paf1 transcriptional complex and controls RNA polymerase II elongation on pluripotency loci. Phf5a also controls differentiation of adult myoblasts.","method":"Loss-of-function (depletion), RNA polymerase II elongation assays, Paf1 complex co-immunoprecipitation, transcriptional analysis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, KD with defined cellular phenotype, multiple orthogonal methods in one study","pmids":["27749823"],"is_preprint":false},{"year":2019,"finding":"PHF5A can be acetylated at lysine 29 (K29) in response to multiple cellular stresses (e.g., nutrient starvation/reduced Acetyl-CoA), and this acetylation is dependent on p300. PHF5A K29 acetylation strengthens interactions among U2 snRNPs and affects global pre-mRNA splicing patterns, including alternative splicing that stabilizes KDM3A mRNA and promotes KDM3A protein expression, contributing to stress resistance in colorectal cancer cells.","method":"Mass spectrometry acetylome analysis, Co-IP, RNA-seq, mutagenesis, in vitro acetylation assay with p300","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical acetylation assay, Co-IP, mutagenesis, and RNA-seq in a single rigorous study","pmids":["31054974"],"is_preprint":false},{"year":2008,"finding":"PHF5A interacts with ATP-dependent helicases EP400 and DDX1 (via its N-terminal region) and with arginine-serine (RS)-rich domains of splicing factors U2AF1 and SFRS5 (via its C-terminal region) in mouse. PHF5A functions as a bridge protein: EP400 and DDX1 interact only indirectly with U2AF1 and SFRS5 via PHF5A. PHF5A-GFP localizes predominantly to the nucleus and co-localizes with U2AF1 and SFRS5 in nuclear speckles of NIH3T3 cells. Interaction between PHF5A and U2AF1 was confirmed in spermatocyte-specific cell line GC-4spc by co-immunoprecipitation.","method":"Yeast two-hybrid, yeast three-hybrid, domain deletion studies, GFP fusion live imaging, co-immunoprecipitation","journal":"Cytogenetic and genome research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Y2H, Y3H, Co-IP, live imaging) establishing bridge function and localization","pmids":["18758164"],"is_preprint":false},{"year":2021,"finding":"Phf5a/Sf3b14b regulates the DNA repair step of class switch recombination (CSR). Loss of Phf5a severely impairs AID-induced recombination without perturbing DNA breaks or somatic hypermutation. Phf5a stabilizes the p400 histone chaperone complex at the immunoglobulin switch (S) region, which promotes deposition of H2A variants H2AX and H2A.Z critical for early DNA damage response and NHEJ-dependent repair, respectively. Depletion of Phf5a or p400 blocks repair of both AID- and I-SceI-induced DNA double-strand breaks.","method":"siRNA loss-of-function screen, chromatin immunoprecipitation, histone variant deposition assays, I-SceI DSB reporter assay, co-immunoprecipitation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with defined molecular mechanism of p400/H2A variant axis","pmids":["33938017"],"is_preprint":false},{"year":2018,"finding":"PHF5A is required for SF3b spliceosome complex stability and links the complex to histones. The PHF5A-SF3b complex modulates alternative splicing changes in apoptotic signaling. PHF5A ablation increases expression of a short truncated FAS-activated serine/threonine kinase (FASTK) protein, facilitating Fas-mediated apoptosis in breast cancer cells. Loss of PHF5A suppresses cell proliferation, migration, and tumor formation.","method":"In vivo CRISPR screen, Co-IP (SF3b complex), RNA-seq, knockdown with proliferation/apoptosis phenotype readout","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screen, Co-IP demonstrating SF3b stability requirement, mechanistic splicing outcome identified","pmids":["29700004"],"is_preprint":false},{"year":2021,"finding":"SIRT7 decrotonylates PHF5A at K25 in senescent fibroblasts. Decrotonylation of PHF5A K25 contributes to decreased CDK2 expression through retained-intron-induced abnormal alternative splicing, thereby accelerating fibroblast senescence.","method":"Mass spectrometry crotonylome profiling, SIRT7 knockdown/overexpression, Western blot, RNA-seq splicing analysis","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — MS identification of modification site, KD/OE with defined phenotype, but single lab","pmids":["34604215"],"is_preprint":false},{"year":2002,"finding":"The C. elegans ortholog of PHF5A (phf-5) is expressed in a muscle-specific, stage-specific manner (pharynx, body wall, anal muscles) during the morphogenetic phase of embryonic development. phf-5 RNAi demonstrates that PHF-5 is essential for morphogenetic development and muscle function in C. elegans embryos and young larvae.","method":"Transgenic phf-5::yfp reporter, RNAi loss-of-function, phenotypic analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct localization experiment tied to functional consequence via RNAi, in C. elegans ortholog","pmids":["12359262"],"is_preprint":false},{"year":2003,"finding":"PHF5A (Ini) localizes to the nucleus of HeLa cells, binds to the proximal connexin43 (cx43) promoter (demonstrated by EMSA), and enhances estrogen-induced upregulation of the cx43 gene in a dose-dependent manner. PHF5A stimulates the transcriptional activating function AF-1 (but not AF-2) of estrogen receptor alpha (ERα), acting as a coactivator specific for AF-1.","method":"Electrophoretic mobility shift assay (EMSA), transient transfection/reporter assay, expression library screening","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2-3 — EMSA and reporter assay establish DNA binding and transcriptional coactivator function, single lab","pmids":["12810571"],"is_preprint":false},{"year":2020,"finding":"In pancreatic cancer stem cells (CSCs), PAF1 interacts with PHF5A and DDX3, forming a PAF1-PHF5A-DDX3 sub-complex that binds to the promoter region of NANOG to regulate stemness. This interaction was independent of the full PAF1C complex identity.","method":"Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation sequencing (ChIP-seq), DDX3 inhibitor rescue experiments","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal Co-IP and ChIP-seq with functional validation, single lab","pmids":["32781084"],"is_preprint":false},{"year":2023,"finding":"KMT2A (a histone methyltransferase) is a physical binding partner of a PHF5A-PHF14-HMG20A-RAI1 protein subcomplex in pancreatic cancer stem cells (PCSCs) and functions as an epigenetic regulator of PCSC properties. Targeting the complex with a KMT2A-WDR5 inhibitor attenuates PCSC self-renewal capacity, cell viability, and in vivo tumorigenicity.","method":"Co-immunoprecipitation, chemical inhibitor (KMT2A-WDR5 inhibitor), in vivo tumor assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP establishes PHF5A complex membership, functional validation with inhibitor in vivo","pmids":["37709746"],"is_preprint":false},{"year":2023,"finding":"PHF5A is phosphorylated at Y36 by the TrkA-ERK1/2-ABL1 signaling cascade. PHF5A is enriched in the centrosome. Phospho-Y36-PHF5A promotes interaction between CEP250 and Nek2A in a spliceosome-independent manner, leading to premature centrosome separation, which remodels microtubules and subsequently regulates cell proliferation and migration. This TrkA-ERK1/2-ABL1-PHF5A phosphorylation cascade is hyper-regulated in medulloblastoma.","method":"Phosphorylation assays, centrosome fractionation, Co-immunoprecipitation (CEP250/Nek2A), mutagenesis (Y36), kinase inhibition","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical phosphorylation, Co-IP, mutagenesis and centrosome localization established, single lab","pmids":["36759599"],"is_preprint":false},{"year":2023,"finding":"De novo heterozygous PHF5A variants (including loss-of-function variants) cause a developmental syndrome with craniofacial abnormalities, developmental delay, and hypospadias. In subject-derived fibroblasts with PHF5A LOF variants, SF3B complex formation was unaffected in 2 subject cell lines, and feedback mechanisms maintain normal levels of SF3B components, suggesting disturbed autoregulation in specific cell types (e.g., neural crest cells) during embryonic development as the pathomechanism rather than simple haploinsufficiency.","method":"Clinical genomics, functional fibroblast studies, transcriptome sequencing, SF3B complex formation assays","journal":"Genetics in medicine","confidence":"Medium","confidence_rationale":"Tier 2 — subject-derived cell functional studies with SF3B complex assays and transcriptome analysis, single study","pmids":["37422718"],"is_preprint":false},{"year":2020,"finding":"CHD4 promotes NSCLC proliferation and migration through its interaction with PHF5A and subsequent activation of the RhoA/ROCK signaling pathway.","method":"CHD4 knockdown/overexpression, Western blot for RhoA/ROCK markers, xenograft mouse model","journal":"BMC cancer","confidence":"Low","confidence_rationale":"Tier 3 — single Co-IP/pulldown with pathway inference, no direct biochemical reconstitution of PHF5A's role","pmids":["32228507"],"is_preprint":false},{"year":2025,"finding":"In avian neural crest (NC) development, DLC1 partners with the SF3B1-PHF5A splicing complex to determine trunk NC cell fate by regulating splicing of NC specifiers SOX9 and SNAI2 pre-mRNAs. SF3B1-PHF5A binds to intronic branch site (BS) sequences of multiple factors, while DLC1 interacts with a specific motif near the BS sequences of SOX9 and SNAI2 to confer specificity. DLC1 increases NC cell vulnerability to splicing modulator pladienolide B (PB) by reducing SF3B1-PHF5A binding capacity to weaker polypyrimidine tracts, causing intron retention.","method":"Protein-protein interaction assays, splicing reporter assays, pladienolide B pharmacology, RNA splicing analysis in avian embryos","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic binding and functional splicing studies in vivo, ortholog context (avian)","pmids":["40691464"],"is_preprint":false},{"year":2023,"finding":"PHF5A silencing in esophageal squamous cell carcinoma (ESCC) promotes VEGFA ubiquitination by enhancing its interaction with the E3 ubiquitin ligase MDM2, thereby reducing VEGFA protein stability. The tumor-promoting effects of PHF5A are dependent on intact VEGFA and PI3K/AKT signaling.","method":"Co-immunoprecipitation (PHF5A-MDM2), ubiquitination assays, microarray, siRNA knockdown, xenograft","journal":"Biology direct","confidence":"Low","confidence_rationale":"Tier 3 — Co-IP with ubiquitination assay, single lab, indirect link to PHF5A's canonical function","pmids":["38429756"],"is_preprint":false},{"year":2023,"finding":"PHF5A regulates alternative splicing of DOCK5 to produce an oncogenic DOCK5 variant in head and neck squamous cell carcinoma (HNSCC), and this promotes HNSCC progression through p38 MAPK pathway activation.","method":"qRT-PCR, siRNA/overexpression, Western blot (p38 MAPK), xenograft, TCGA correlation","journal":"Biology direct","confidence":"Low","confidence_rationale":"Tier 3 — functional phenotype with pathway association, but mechanistic link between PHF5A splicing activity and p38 is indirect","pmids":["37434235"],"is_preprint":false}],"current_model":"PHF5A is a highly conserved PHD-finger protein and core component of the SF3b subcomplex of U2 snRNP that directly contacts the branch point adenosine pocket (together with SF3B1) to regulate pre-mRNA splicing; it is subject to post-translational modifications (p300-mediated acetylation at K29, SIRT7-mediated decrotonylation at K25, and TrkA-ERK1/2-ABL1-mediated phosphorylation at Y36) that modulate its interactions with U2 snRNP components and non-canonical partners (p400, CEP250/Nek2A at centrosomes), enabling it to control alternative splicing of cancer-relevant genes, regulate RNA polymerase II elongation via the Paf1 complex in stem cells, and mediate NHEJ-dependent DNA repair through histone H2A variant deposition, with its Y36 residue also representing the binding site for clinical splicing modulator drugs."},"narrative":{"teleology":[{"year":2002,"claim":"The earliest functional data established that a PHF5A ortholog is essential for embryonic morphogenesis, indicating a fundamental developmental role before any molecular mechanism was known.","evidence":"C. elegans phf-5::yfp reporter and RNAi in embryos showing muscle-specific expression and lethality upon knockdown","pmids":["12359262"],"confidence":"Medium","gaps":["Mechanism of action in muscle development unknown","No link to splicing or chromatin at this stage"]},{"year":2003,"claim":"PHF5A was shown to function as a nuclear transcriptional coactivator, establishing its role in gene regulation via direct promoter binding and estrogen receptor AF-1 coactivation.","evidence":"EMSA on cx43 promoter and reporter assays in HeLa cells","pmids":["12810571"],"confidence":"Medium","gaps":["Coactivator function not connected to splicing machinery","Single promoter target tested","No structural insight into DNA-binding mode"]},{"year":2008,"claim":"PHF5A was identified as a molecular bridge linking the chromatin remodeler EP400/DDX1 to splicing factors U2AF1/SFRS5, placing it at the intersection of chromatin and splicing for the first time.","evidence":"Yeast two-hybrid, three-hybrid, Co-IP, and nuclear speckle colocalization in NIH3T3 cells","pmids":["18758164"],"confidence":"High","gaps":["Functional consequence of bridging not tested","Endogenous complex stoichiometry unresolved"]},{"year":2013,"claim":"PHF5A was demonstrated to be essential for U2 snRNP-dependent recognition of C-rich 3′ splice sites in thousands of essential genes, establishing it as a critical splicing factor with cancer-specific vulnerability in glioblastoma stem cells.","evidence":"Genome-wide RNAi screen, RNA-seq, pharmacologic U2 snRNP inhibition, in vivo xenograft in GSCs vs. normal cells","pmids":["23651857"],"confidence":"High","gaps":["Structural basis for C-rich splice site preference unknown","Whether this selectivity is intrinsic to PHF5A or an emergent SF3b property unclear"]},{"year":2016,"claim":"PHF5A was shown to have a splicing-independent transcriptional role: stabilizing the Paf1 complex and controlling RNA Pol II elongation at pluripotency loci, resolving how it maintains ESC self-renewal.","evidence":"Paf1 complex Co-IP, Pol II elongation assays, and differentiation phenotype upon Phf5a depletion in mouse ESCs and myoblasts","pmids":["27749823"],"confidence":"High","gaps":["Whether Paf1 stabilization is direct or via splicing of Paf1 subunit mRNAs was not fully excluded","Structural basis of Paf1–PHF5A interaction unresolved"]},{"year":2017,"claim":"The crystal structure of PHF5A and cryo-EM of the spliceosome revealed that PHF5A-Y36 and SF3B1 residues form the branch point adenosine-binding pocket, which is also the target of clinical splicing modulators pladienolide, herboxidiene, and spliceostatin.","evidence":"Crystal structure of human PHF5A, cryo-EM of Bact complex, Y36C mutagenesis conferring drug resistance, RNA-seq","pmids":["28541300"],"confidence":"High","gaps":["Full atomic model of drug bound in the pocket not resolved in this study","Mechanism of GC-content-dependent differential sensitivity not fully explained"]},{"year":2018,"claim":"PHF5A was shown to be required for SF3b complex stability and to link the spliceosome to histones; its loss altered alternative splicing of apoptotic regulators including FASTK, sensitizing breast cancer cells to Fas-mediated apoptosis.","evidence":"In vivo CRISPR screen, Co-IP of SF3b complex, RNA-seq, proliferation and apoptosis assays","pmids":["29700004"],"confidence":"High","gaps":["Nature of histone linkage (direct binding vs. indirect) not structurally resolved","Whether FASTK splicing change is direct or secondary unclear"]},{"year":2019,"claim":"p300-mediated acetylation of PHF5A at K29 was identified as a stress-responsive post-translational switch that strengthens U2 snRNP assembly and globally reprograms alternative splicing, including stabilization of KDM3A mRNA in colorectal cancer.","evidence":"Acetylome MS, in vitro p300 acetylation, Co-IP of U2 snRNP components, K29 mutagenesis, RNA-seq","pmids":["31054974"],"confidence":"High","gaps":["Deacetylase counteracting p300 at K29 not identified","Whether K29ac and K25 crotonylation are mutually exclusive or co-regulated is unknown"]},{"year":2020,"claim":"A PAF1–PHF5A–DDX3 sub-complex was found to bind the NANOG promoter in pancreatic cancer stem cells, extending PHF5A's transcriptional role to stemness regulation independent of the canonical PAF1C.","evidence":"Reciprocal Co-IP, mass spectrometry, ChIP-seq, DDX3 inhibitor rescue in pancreatic CSCs","pmids":["32781084"],"confidence":"Medium","gaps":["Whether this complex acts via chromatin remodeling or transcriptional elongation is not distinguished","Generalizability beyond pancreatic CSCs untested"]},{"year":2021,"claim":"PHF5A was established as a DNA repair factor: it stabilizes p400 at immunoglobulin switch regions to deposit H2A.Z and γH2AX, enabling NHEJ-dependent repair of AID-induced and I-SceI-induced DSBs during class switch recombination.","evidence":"siRNA screen, ChIP for p400 and H2A variants at S regions, I-SceI DSB reporter, Co-IP","pmids":["33938017"],"confidence":"High","gaps":["Whether PHF5A's role in DSB repair is spliceosome-dependent or independent not resolved","Direct PHF5A–p400 binding interface unknown"]},{"year":2021,"claim":"SIRT7-mediated decrotonylation of PHF5A at K25 was identified as a second acyl modification that modulates splicing, specifically causing intron retention in CDK2 mRNA to drive cellular senescence.","evidence":"Crotonylome MS, SIRT7 KD/OE, RNA-seq splicing analysis in fibroblasts","pmids":["34604215"],"confidence":"Medium","gaps":["Crotonylation writer enzyme unknown","Single-lab finding not independently confirmed","Whether K25 modification affects U2 snRNP assembly as K29ac does is untested"]},{"year":2023,"claim":"Phosphorylation of PHF5A at Y36 by TrkA-ERK1/2-ABL1 was shown to drive a spliceosome-independent centrosomal function—promoting CEP250–Nek2A interaction and premature centrosome separation—demonstrating that the same residue targeted by splicing drugs also mediates a distinct non-splicing activity relevant to medulloblastoma.","evidence":"Phosphorylation assays, centrosome fractionation, Co-IP of CEP250/Nek2A, Y36 mutagenesis, kinase inhibitors","pmids":["36759599"],"confidence":"Medium","gaps":["Single-lab study; centrosomal localization not confirmed by independent methods","Whether Y36 phosphorylation and drug binding are mutually exclusive not tested","Structural basis for CEP250/Nek2A interaction unknown"]},{"year":2023,"claim":"De novo heterozygous PHF5A variants were identified as causative for a Mendelian developmental syndrome, establishing PHF5A haploinsufficiency as pathogenic in human development while revealing feedback autoregulation of SF3B complex levels.","evidence":"Clinical genomics in multiple families, fibroblast SF3B complex assays, transcriptome sequencing","pmids":["37422718"],"confidence":"Medium","gaps":["Pathogenic mechanism in neural crest cells specifically not directly demonstrated","Number of affected individuals still small","Genotype-phenotype correlation across variant types not established"]},{"year":2023,"claim":"PHF5A was placed within a PHF5A–PHF14–HMG20A–RAI1–KMT2A complex in pancreatic cancer stem cells, linking it to histone H3K4 methylation and epigenetic maintenance of stemness.","evidence":"Co-IP, KMT2A-WDR5 inhibitor, in vivo tumor assay in pancreatic CSCs","pmids":["37709746"],"confidence":"Medium","gaps":["Whether PHF5A directly contacts KMT2A is unknown","Stoichiometry and stability of this complex not characterized"]},{"year":2025,"claim":"In avian neural crest development, DLC1 was shown to partner with SF3B1–PHF5A to confer target specificity for splicing of SOX9 and SNAI2, revealing how a non-spliceosome accessory factor co-opts the PHF5A branch-point recognition machinery to determine cell fate.","evidence":"Protein-protein interaction assays, splicing reporters, pladienolide B pharmacology, in vivo avian embryo RNA splicing analysis","pmids":["40691464"],"confidence":"Medium","gaps":["Generalizability to mammalian neural crest not shown","Whether DLC1 interaction is conserved in human PHF5A untested"]},{"year":null,"claim":"Key unresolved questions include: (1) how PHF5A's splicing-dependent and splicing-independent functions (Paf1 stabilization, centrosome regulation, DNA repair) are coordinately regulated; (2) the interplay among multiple acyl modifications (K29 acetylation, K25 crotonylation) and Y36 phosphorylation; and (3) the cell-type-specific pathomechanism underlying the PHF5A-associated developmental syndrome.","evidence":"","pmids":[],"confidence":"Low","gaps":["No integrative model of PTM cross-talk on PHF5A","Tissue-specific splicing targets during embryonic development uncharacterized","Full atomic structure of PHF5A within the drug-bound SF3b complex not yet available"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,1,3,15]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,9,10]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[5,6]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,9]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[4]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,1,3,6,7,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,9,10]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[5]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,13,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,6,11]}],"complexes":["SF3b (U2 snRNP)","PAF1-PHF5A-DDX3","PHF5A-PHF14-HMG20A-RAI1-KMT2A"],"partners":["SF3B1","EP400","U2AF1","PAF1","DDX3","CEP250","NEK2","DLC1"],"other_free_text":[]},"mechanistic_narrative":"PHF5A is a highly conserved PHD-finger protein that functions as a core subunit of the SF3b subcomplex of U2 snRNP, where it directly contacts the branch point adenosine pocket together with SF3B1 to regulate constitutive and alternative pre-mRNA splicing [PMID:28541300, PMID:23651857]. PHF5A is subject to post-translational modifications—p300-mediated acetylation at K29 strengthens U2 snRNP interactions and modulates stress-responsive splicing [PMID:31054974], SIRT7-mediated decrotonylation at K25 alters CDK2 splicing to promote senescence [PMID:34604215], and TrkA-ERK1/2-ABL1-mediated phosphorylation at Y36 drives a spliceosome-independent centrosomal function by promoting CEP250–Nek2A interaction and premature centrosome separation [PMID:36759599]. Beyond splicing, PHF5A stabilizes the Paf1 transcriptional elongation complex at pluripotency loci in embryonic stem cells [PMID:27749823] and recruits the p400 histone chaperone to immunoglobulin switch regions to deposit H2A.Z and γH2AX for NHEJ-dependent DNA double-strand break repair during class switch recombination [PMID:33938017]. De novo heterozygous PHF5A loss-of-function variants cause a developmental syndrome featuring craniofacial abnormalities, developmental delay, and hypospadias [PMID:37422718]."},"prefetch_data":{"uniprot":{"accession":"Q7RTV0","full_name":"PHD finger-like domain-containing protein 5A","aliases":["Splicing factor 3B-associated 14 kDa protein","SF3b14b"],"length_aa":110,"mass_kda":12.4,"function":"Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs (PubMed:12234937, PubMed:27720643, PubMed:28541300, PubMed:32494006, PubMed:34822310). The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing (PubMed:12234937, PubMed:32494006, PubMed:34822310). Within the 17S U2 SnRNP complex, PHF5A is part of the SF3B subcomplex, which is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA (PubMed:12234937, PubMed:27720643). Sequence independent binding of SF3A and SF3B subcomplexes upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA (PubMed:12234937). Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs (PubMed:15146077, PubMed:33509932). Also involved in elongation by RNA polymerase II as part of the PAF1 complex (PAF1C) (By similarity). PAF1C is required for maintenance of embryonic stem cell (ESC) self-renewal and cellular reprogramming of stem cells (By similarity). Maintains pluripotency by recruiting and stabilizing PAF1C on pluripotency genes loci, and by regulating the expression of the pluripotency genes (By similarity). Regulates the deposition of elongation-associated histone modifications, including dimethylated histone H3 'Lys-79' (H3K79me2) and trimethylated histone H3 'Lys-36' (H3K36me3), on PAF1C targets, self-renewal and pluripotency genes (By similarity). Regulates RNA polymerase II promoter-proximal pause release of the PAF1C targets and self-renewal genes, and the levels of elongating ('Ser-2' phosphorylated) RNA polymerase II in their gene bodies (By similarity). Regulates muscle specification in adult stem cells by stabilizing PAF1C in chromatin to promote myogenic differentiation (By similarity). Acts as a transcriptional regulator by binding to the GJA1/Cx43 promoter and enhancing its up-regulation by ESR1/ER-alpha (By similarity)","subcellular_location":"Nucleus; Nucleus speckle","url":"https://www.uniprot.org/uniprotkb/Q7RTV0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/PHF5A","classification":"Common Essential","n_dependent_lines":1208,"n_total_lines":1208,"dependency_fraction":1.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SF3B1","stoichiometry":4.0},{"gene":"COMMD6","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"RBM39","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PHF5A","total_profiled":1310},"omim":[{"mim_id":"617846","title":"PHD FINGER PROTEIN 5A; PHF5A","url":"https://www.omim.org/entry/617846"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PHF5A"},"hgnc":{"alias_symbol":["MGC1346","SF3b14b","INI","bK223H9.2","Rds3","SAP14b","SF3B7"],"prev_symbol":[]},"alphafold":{"accession":"Q7RTV0","domains":[{"cath_id":"-","chopping":"20-104","consensus_level":"high","plddt":91.9285,"start":20,"end":104}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7RTV0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q7RTV0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q7RTV0-F1-predicted_aligned_error_v6.png","plddt_mean":89.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PHF5A","jax_strain_url":"https://www.jax.org/strain/search?query=PHF5A"},"sequence":{"accession":"Q7RTV0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q7RTV0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q7RTV0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7RTV0"}},"corpus_meta":[{"pmid":"28291122","id":"PMC_28291122","title":"SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28291122","citation_count":184,"is_preprint":false},{"pmid":"25007146","id":"PMC_25007146","title":"SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25007146","citation_count":150,"is_preprint":false},{"pmid":"28541300","id":"PMC_28541300","title":"Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28541300","citation_count":117,"is_preprint":false},{"pmid":"23651857","id":"PMC_23651857","title":"Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23651857","citation_count":106,"is_preprint":false},{"pmid":"27587586","id":"PMC_27587586","title":"Genome-wide identification and characterisation of human DNA replication origins by initiation site sequencing (ini-seq).","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27587586","citation_count":90,"is_preprint":false},{"pmid":"31054974","id":"PMC_31054974","title":"Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31054974","citation_count":82,"is_preprint":false},{"pmid":"20118769","id":"PMC_20118769","title":"Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6.","date":"2010","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20118769","citation_count":79,"is_preprint":false},{"pmid":"29700004","id":"PMC_29700004","title":"PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29700004","citation_count":69,"is_preprint":false},{"pmid":"26311843","id":"PMC_26311843","title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.","date":"2015","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26311843","citation_count":68,"is_preprint":false},{"pmid":"27749823","id":"PMC_27749823","title":"Regulation of transcriptional elongation in pluripotency and cell differentiation by the PHD-finger protein Phf5a.","date":"2016","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27749823","citation_count":60,"is_preprint":false},{"pmid":"32781084","id":"PMC_32781084","title":"RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A and DDX3.","date":"2020","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32781084","citation_count":58,"is_preprint":false},{"pmid":"22260386","id":"PMC_22260386","title":"p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.","date":"2012","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22260386","citation_count":54,"is_preprint":false},{"pmid":"31468350","id":"PMC_31468350","title":"SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features.","date":"2019","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31468350","citation_count":51,"is_preprint":false},{"pmid":"21705046","id":"PMC_21705046","title":"Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma.","date":"2011","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/21705046","citation_count":37,"is_preprint":false},{"pmid":"34604215","id":"PMC_34604215","title":"SIRT7-Induced PHF5A Decrotonylation Regulates Aging Progress Through Alternative Splicing-Mediated Downregulation of CDK2.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34604215","citation_count":36,"is_preprint":false},{"pmid":"32228507","id":"PMC_32228507","title":"CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32228507","citation_count":34,"is_preprint":false},{"pmid":"12810571","id":"PMC_12810571","title":"Ini, a small nuclear protein that enhances the response of the connexin43 gene to estrogen.","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12810571","citation_count":27,"is_preprint":false},{"pmid":"18758164","id":"PMC_18758164","title":"PHF5A represents a bridge protein between splicing proteins and ATP-dependent helicases and is differentially expressed during mouse spermatogenesis.","date":"2008","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/18758164","citation_count":22,"is_preprint":false},{"pmid":"21566521","id":"PMC_21566521","title":"Intra-articular epithelioid sarcoma showing mixed classic and proximal-type features: report of 2 cases, with immunohistochemical and molecular cytogenetic INI-1 study.","date":"2011","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21566521","citation_count":22,"is_preprint":false},{"pmid":"12359262","id":"PMC_12359262","title":"The Caenorhabditis elegans ortholog of human PHF5a shows a muscle-specific expression domain and is essential for C. elegans morphogenetic development.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12359262","citation_count":21,"is_preprint":false},{"pmid":"33938017","id":"PMC_33938017","title":"Phf5a regulates DNA repair in class switch recombination via p400 and histone H2A variant deposition.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/33938017","citation_count":20,"is_preprint":false},{"pmid":"23161234","id":"PMC_23161234","title":"Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma.","date":"2012","source":"Polish journal of pathology : official journal of the Polish Society of Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/23161234","citation_count":20,"is_preprint":false},{"pmid":"30766880","id":"PMC_30766880","title":"Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-κB Signaling.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/30766880","citation_count":19,"is_preprint":false},{"pmid":"34265804","id":"PMC_34265804","title":"Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34265804","citation_count":19,"is_preprint":false},{"pmid":"27177850","id":"PMC_27177850","title":"Cytopathologic characteristics of SMARCB1 (INI-1) deficient sinonasal carcinoma: A potential diagnostic pitfall.","date":"2016","source":"Diagnostic cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27177850","citation_count":19,"is_preprint":false},{"pmid":"33824593","id":"PMC_33824593","title":"Case Report: SMARCB1 (INI-1)-Deficient Carcinoma of the Nasal Cavity with Pure Yolk Sac Tumor Differentiation and Elevated Serum AFP Levels.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33824593","citation_count":19,"is_preprint":false},{"pmid":"32337786","id":"PMC_32337786","title":"INI-1 (SMARCB1)-Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies.","date":"2020","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/32337786","citation_count":18,"is_preprint":false},{"pmid":"23675859","id":"PMC_23675859","title":"Expression patterns of Phf5a/PHF5A and Gja1/GJA1 in rat and human endometrial cancer.","date":"2013","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/23675859","citation_count":17,"is_preprint":false},{"pmid":"29797680","id":"PMC_29797680","title":"Cytopathologic features of SMARCB1 (INI-1)-deficient sinonasal carcinoma.","date":"2018","source":"Cancer cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/29797680","citation_count":15,"is_preprint":false},{"pmid":"29793524","id":"PMC_29793524","title":"A central-acting connexin inhibitor, INI-0602, prevents high-fat diet-induced feeding pattern disturbances and obesity in mice.","date":"2018","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/29793524","citation_count":15,"is_preprint":false},{"pmid":"30741784","id":"PMC_30741784","title":"The gap junction inhibitor INI-0602 attenuates mechanical allodynia and depression-like behaviors induced by spared nerve injury in rats.","date":"2019","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/30741784","citation_count":13,"is_preprint":false},{"pmid":"37709746","id":"PMC_37709746","title":"KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37709746","citation_count":12,"is_preprint":false},{"pmid":"25755805","id":"PMC_25755805","title":"Beware of immunohistochemistry--report of a cytokeratin-, desmin- and INI-1-negative pelvic desmoplastic small round cell tumor in a 51 year old woman.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25755805","citation_count":11,"is_preprint":false},{"pmid":"24744047","id":"PMC_24744047","title":"Protective effect of INI-0602, a gap junction inhibitor, on dopaminergic neurodegeneration of mice with unilateral 6-hydroxydopamine injection.","date":"2014","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/24744047","citation_count":11,"is_preprint":false},{"pmid":"36609277","id":"PMC_36609277","title":"PHF5A facilitates the development and progression of gastric cancer through SKP2-mediated stabilization of FOS.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36609277","citation_count":10,"is_preprint":false},{"pmid":"35777798","id":"PMC_35777798","title":"PHF5A Contributes to the Maintenance of the Cancer Stem-like Phenotype in Non-Small Cell Lung Cancer by Regulating Histone Deacetylase 8.","date":"2022","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/35777798","citation_count":10,"is_preprint":false},{"pmid":"31729110","id":"PMC_31729110","title":"SMARCB1 (INI-1) and NUT immunoexpression in a large series of head and neck carcinomas in a Brazilian reference center.","date":"2019","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/31729110","citation_count":9,"is_preprint":false},{"pmid":"31132763","id":"PMC_31132763","title":"Metastatic SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma Diagnosed by Endobronchial Ultrasound-Guided Fine-Needle Aspiration (EBUS-FNA): A Potential Diagnostic Pitfall and Review of the Literature.","date":"2019","source":"Acta cytologica","url":"https://pubmed.ncbi.nlm.nih.gov/31132763","citation_count":8,"is_preprint":false},{"pmid":"38073679","id":"PMC_38073679","title":"Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports.","date":"2023","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/38073679","citation_count":7,"is_preprint":false},{"pmid":"35758187","id":"PMC_35758187","title":"A Subset of SMARCB1 (INI-1)-deficient vulvar neoplasms express germ cell markers.","date":"2022","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/35758187","citation_count":7,"is_preprint":false},{"pmid":"28974397","id":"PMC_28974397","title":"Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.","date":"2017","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28974397","citation_count":7,"is_preprint":false},{"pmid":"27651667","id":"PMC_27651667","title":"Risk factors associated with Cryptosporidia, Eimeria, and diarrhea in smallholder dairy farms in Mukurwe-ini Sub-County, Nyeri County, Kenya.","date":"2016","source":"Veterinary world","url":"https://pubmed.ncbi.nlm.nih.gov/27651667","citation_count":7,"is_preprint":false},{"pmid":"25973116","id":"PMC_25973116","title":"Atypical ossifying fibromyxoid tumor unusually located in the mediastinum: report of a case showing mosaic loss of INI-1 expression.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25973116","citation_count":6,"is_preprint":false},{"pmid":"37422718","id":"PMC_37422718","title":"De novo PHF5A variants are associated with craniofacial abnormalities, developmental delay, and hypospadias.","date":"2023","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37422718","citation_count":5,"is_preprint":false},{"pmid":"37434235","id":"PMC_37434235","title":"PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation.","date":"2023","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/37434235","citation_count":5,"is_preprint":false},{"pmid":"24475586","id":"PMC_24475586","title":"Immunoreactivity for Ca 125 and INI 1 loss of expression are useful markers in the diagnosis of vulvar proximal-type epithelioid sarcomas: report of two cases.","date":"2013","source":"European journal of gynaecological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24475586","citation_count":5,"is_preprint":false},{"pmid":"34048096","id":"PMC_34048096","title":"tRNAIni CAT inhibits proliferation and promotes apoptosis of laryngeal squamous cell carcinoma cells.","date":"2021","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/34048096","citation_count":4,"is_preprint":false},{"pmid":"37218455","id":"PMC_37218455","title":"Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.","date":"2023","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37218455","citation_count":4,"is_preprint":false},{"pmid":"25397500","id":"PMC_25397500","title":"Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.","date":"2014","source":"Journal of the International AIDS Society","url":"https://pubmed.ncbi.nlm.nih.gov/25397500","citation_count":4,"is_preprint":false},{"pmid":"37378241","id":"PMC_37378241","title":"Subependymal Giant Cell Astrocytoma Non-Associated With Tuberous Sclerosis Complex and Expression of OCT-4 and INI-1: A Case Report.","date":"2023","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/37378241","citation_count":4,"is_preprint":false},{"pmid":"37483794","id":"PMC_37483794","title":"PHF5A as a new OncoTarget and therapeutic prospects.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/37483794","citation_count":3,"is_preprint":false},{"pmid":"40691464","id":"PMC_40691464","title":"Determination of trunk neural crest cell fate and susceptibility to splicing perturbation by the DLC1-SF3B1-PHF5A splicing complex.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40691464","citation_count":3,"is_preprint":false},{"pmid":"40670406","id":"PMC_40670406","title":"The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.","date":"2025","source":"NPJ vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/40670406","citation_count":3,"is_preprint":false},{"pmid":"32011562","id":"PMC_32011562","title":"A Nonchordomatous-looking Chordoma: When INI-1 and Radiology Came to the Rescue!!!","date":"2020","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32011562","citation_count":3,"is_preprint":false},{"pmid":"26045850","id":"PMC_26045850","title":"Cystic synovial sarcoma of the pleura mimicking a cystic thymoma: a case report illustrating the role of decreased INI-1 expression in differential diagnosis.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26045850","citation_count":3,"is_preprint":false},{"pmid":"39370125","id":"PMC_39370125","title":"Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis.","date":"2024","source":"Infection & chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39370125","citation_count":3,"is_preprint":false},{"pmid":"36759599","id":"PMC_36759599","title":"The phosphorylation of PHF5A by TrkA-ERK1/2-ABL1 cascade regulates centrosome separation.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36759599","citation_count":2,"is_preprint":false},{"pmid":"39212334","id":"PMC_39212334","title":"Splicing control by PHF5A is crucial for melanoma cell survival.","date":"2024","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/39212334","citation_count":2,"is_preprint":false},{"pmid":"37345372","id":"PMC_37345372","title":"Genome-wide temporal landscaping of DNA methylation in pregnant women delivering at term: a GARBH-InI study.","date":"2023","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/37345372","citation_count":2,"is_preprint":false},{"pmid":"37876879","id":"PMC_37876879","title":"Underreporting of SMARCB1 alteration by clinical sequencing: Integrative patho-genomic analysis captured SMARCB1/INI-1 deficiency in a vulvar yolk sac tumor.","date":"2023","source":"Gynecologic oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/37876879","citation_count":2,"is_preprint":false},{"pmid":"39108263","id":"PMC_39108263","title":"Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39108263","citation_count":2,"is_preprint":false},{"pmid":"36792075","id":"PMC_36792075","title":"[PHF5A Promotes Proliferation and Migration of Non-Small Cell Lung Cancer 
by Regulating of PI3K/AKT Pathway].","date":"2023","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36792075","citation_count":2,"is_preprint":false},{"pmid":"10753612","id":"PMC_10753612","title":"Resonant Coherent Anti-Stokes Raman Scattering Applied to Vapor Phase InI.","date":"2000","source":"Journal of molecular spectroscopy","url":"https://pubmed.ncbi.nlm.nih.gov/10753612","citation_count":2,"is_preprint":false},{"pmid":"35900556","id":"PMC_35900556","title":"Reappraisal of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1/INI-1 deficient tumor: Report of two cases.","date":"2022","source":"Journal of cancer research and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35900556","citation_count":2,"is_preprint":false},{"pmid":"36581580","id":"PMC_36581580","title":"Research progress and therapeutic prospect of PHF5A acting as a new target for malignant tumors.","date":"2022","source":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36581580","citation_count":1,"is_preprint":false},{"pmid":"38429756","id":"PMC_38429756","title":"PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA.","date":"2024","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/38429756","citation_count":1,"is_preprint":false},{"pmid":"39677812","id":"PMC_39677812","title":"The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39677812","citation_count":1,"is_preprint":false},{"pmid":"12684622","id":"PMC_12684622","title":"INI-1, a partner gene of ALL-1, is highly conserved in human acute leukemia.","date":"2003","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/12684622","citation_count":1,"is_preprint":false},{"pmid":"39106742","id":"PMC_39106742","title":"SMARCB1 (INI-1) deficient sinonasal carcinoma of the right maxillary sinus - A rare entity.","date":"2024","source":"International journal of surgery case reports","url":"https://pubmed.ncbi.nlm.nih.gov/39106742","citation_count":1,"is_preprint":false},{"pmid":"28541826","id":"PMC_28541826","title":"INI Expressing Epithelioid Sarcoma with Osteoclastic Giant Cells in a Child: A Case Report with Summary of Prior Published Cases.","date":"2017","source":"Fetal and pediatric pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28541826","citation_count":1,"is_preprint":false},{"pmid":"41066470","id":"PMC_41066470","title":"SMARCB1 (INI-1)-Deficient Myoepithelioma-Like Tumor in the Perineal Region of a Male Patient: A Case Report.","date":"2025","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41066470","citation_count":1,"is_preprint":false},{"pmid":"36514645","id":"PMC_36514645","title":"A Novel Successful Case of Nasal and Sinus Yolk Sac Tumor With SMARCB1 (INI-1) Deficiency: A Case Report.","date":"2022","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/36514645","citation_count":0,"is_preprint":false},{"pmid":"33680622","id":"PMC_33680622","title":"Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma.","date":"2021","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/33680622","citation_count":0,"is_preprint":false},{"pmid":"35866278","id":"PMC_35866278","title":"[Analysis of the diagnosis and treatment of patients with SMARCB1 (INI-1)-deficient sinonasal carcinoma].","date":"2022","source":"Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/35866278","citation_count":0,"is_preprint":false},{"pmid":"21050911","id":"PMC_21050911","title":"Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.","date":"2010","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/21050911","citation_count":0,"is_preprint":false},{"pmid":"40291911","id":"PMC_40291911","title":"Metastatic INI-1-deficient undifferentiated lung cancer with EGFR 19del mutation identified in pleural effusion: a case report and review of the literature.","date":"2025","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40291911","citation_count":0,"is_preprint":false},{"pmid":"37077082","id":"PMC_37077082","title":"SMARCB1 (INI-1) - Deficient sinonasal carcinoma: Report of two cases.","date":"2023","source":"Indian journal of pathology & microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/37077082","citation_count":0,"is_preprint":false},{"pmid":"39925590","id":"PMC_39925590","title":"Adaptive Treatment Strategy: Adjuvant Chemoradiotherapy for a Complex SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma With Intracranial Extension.","date":"2025","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/39925590","citation_count":0,"is_preprint":false},{"pmid":"41291778","id":"PMC_41291778","title":"SMARCB1 (INI-1) deficient vulvar neoplasms: report of 4 cases with review of literature.","date":"2025","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41291778","citation_count":0,"is_preprint":false},{"pmid":"41457811","id":"PMC_41457811","title":"Cytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI-1) Deficient Diagnosed by Ultrasound-Guided Fine-Needle Aspiration: A Case Report.","date":"2025","source":"Diagnostic cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/41457811","citation_count":0,"is_preprint":false},{"pmid":"40660065","id":"PMC_40660065","title":"Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses.","date":"2025","source":"Drug delivery and translational research","url":"https://pubmed.ncbi.nlm.nih.gov/40660065","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.08.631964","title":"A cationic liposome-formulated Toll Like Receptor (TLR)7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity","date":"2025-01-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.08.631964","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.20.665773","title":"Identification of RNA binding proteins that mediate a quality control mechanism of splicing","date":"2025-07-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.20.665773","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.12.628169","title":"A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs","date":"2024-12-17","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.12.628169","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.18.25327852","title":"Phenotypic Characteristics Associated with Preterm Births in the Indian Population","date":"2025-05-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.18.25327852","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.21.24309323","title":"Alzheimer’s disease as a form of in situ diabetes: A systematic review and meta-analysis of therapeutic approaches using intranasal insulin treatment","date":"2024-06-25","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.21.24309323","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.05.13.24305466","title":"Development and external validation of an ultrasound image-based deep learning model to estimate gestational age in the second and third trimesters of pregnancy using data from Garbh-Ini cohort: a prospective cohort study in North Indian population","date":"2024-05-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.13.24305466","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46736,"output_tokens":4853,"usd":0.106501},"stage2":{"model":"claude-opus-4-6","input_tokens":8309,"output_tokens":3903,"usd":0.20868},"total_usd":0.315181,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"PHF5A, a component of the SF3b subcomplex, is targeted by splicing modulators pladienolide, herboxidiene, and spliceostatin. Mutations in PHF5A-Y36, SF3B1-K1071, SF3B1-R1074, and SF3B1-V1078 confer resistance to these modulators, indicating a common interaction site. Crystal structure of human PHF5A shows Y36 is located on a highly conserved surface, and cryo-EM analysis of the spliceosome Bact complex shows the resistance mutations cluster in a pocket surrounding the branch point adenosine, suggesting competitive binding. PHF5A-Y36C has minimal effect on basal splicing but inhibits the global action of these splicing modulators and alters their induced intron-retention/exon-skipping profile correlating with GC content of adjacent introns and exons.\",\n      \"method\": \"Crystal structure determination, cryo-EM spliceosome analysis, mutagenesis resistance studies, RNA-seq analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure, cryo-EM, mutagenesis, and functional RNA-seq in a single study\",\n      \"pmids\": [\"28541300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PHF5A facilitates recognition of exons with unusual C-rich 3' splice sites in thousands of essential genes in glioblastoma stem cells (GSCs). PHF5A knockdown in GSCs inhibits splicing of these genes, leading to cell cycle arrest and loss of viability, while having minimal effect in untransformed neural stem cells, astrocytes, or fibroblasts. Pharmacologic inhibition of U2 snRNP activity phenocopied PHF5A knockdown. PHF5A inhibition also compromised GSC tumor formation in vivo and inhibited growth of established GBM patient-derived xenograft tumors.\",\n      \"method\": \"Genome-wide RNAi screen, RNA-seq, pharmacologic inhibition, in vivo xenograft experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide screen, mechanistic RNA-seq, in vivo validation with clean KD phenotype\",\n      \"pmids\": [\"23651857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Phf5a is essential for maintaining pluripotency in embryonic stem cells (ESCs); depletion leads to differentiation. Mechanistically, Phf5a stabilizes the Paf1 transcriptional complex and controls RNA polymerase II elongation on pluripotency loci. Phf5a also controls differentiation of adult myoblasts.\",\n      \"method\": \"Loss-of-function (depletion), RNA polymerase II elongation assays, Paf1 complex co-immunoprecipitation, transcriptional analysis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, KD with defined cellular phenotype, multiple orthogonal methods in one study\",\n      \"pmids\": [\"27749823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PHF5A can be acetylated at lysine 29 (K29) in response to multiple cellular stresses (e.g., nutrient starvation/reduced Acetyl-CoA), and this acetylation is dependent on p300. PHF5A K29 acetylation strengthens interactions among U2 snRNPs and affects global pre-mRNA splicing patterns, including alternative splicing that stabilizes KDM3A mRNA and promotes KDM3A protein expression, contributing to stress resistance in colorectal cancer cells.\",\n      \"method\": \"Mass spectrometry acetylome analysis, Co-IP, RNA-seq, mutagenesis, in vitro acetylation assay with p300\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical acetylation assay, Co-IP, mutagenesis, and RNA-seq in a single rigorous study\",\n      \"pmids\": [\"31054974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PHF5A interacts with ATP-dependent helicases EP400 and DDX1 (via its N-terminal region) and with arginine-serine (RS)-rich domains of splicing factors U2AF1 and SFRS5 (via its C-terminal region) in mouse. PHF5A functions as a bridge protein: EP400 and DDX1 interact only indirectly with U2AF1 and SFRS5 via PHF5A. PHF5A-GFP localizes predominantly to the nucleus and co-localizes with U2AF1 and SFRS5 in nuclear speckles of NIH3T3 cells. Interaction between PHF5A and U2AF1 was confirmed in spermatocyte-specific cell line GC-4spc by co-immunoprecipitation.\",\n      \"method\": \"Yeast two-hybrid, yeast three-hybrid, domain deletion studies, GFP fusion live imaging, co-immunoprecipitation\",\n      \"journal\": \"Cytogenetic and genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Y2H, Y3H, Co-IP, live imaging) establishing bridge function and localization\",\n      \"pmids\": [\"18758164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Phf5a/Sf3b14b regulates the DNA repair step of class switch recombination (CSR). Loss of Phf5a severely impairs AID-induced recombination without perturbing DNA breaks or somatic hypermutation. Phf5a stabilizes the p400 histone chaperone complex at the immunoglobulin switch (S) region, which promotes deposition of H2A variants H2AX and H2A.Z critical for early DNA damage response and NHEJ-dependent repair, respectively. Depletion of Phf5a or p400 blocks repair of both AID- and I-SceI-induced DNA double-strand breaks.\",\n      \"method\": \"siRNA loss-of-function screen, chromatin immunoprecipitation, histone variant deposition assays, I-SceI DSB reporter assay, co-immunoprecipitation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with defined molecular mechanism of p400/H2A variant axis\",\n      \"pmids\": [\"33938017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PHF5A is required for SF3b spliceosome complex stability and links the complex to histones. The PHF5A-SF3b complex modulates alternative splicing changes in apoptotic signaling. PHF5A ablation increases expression of a short truncated FAS-activated serine/threonine kinase (FASTK) protein, facilitating Fas-mediated apoptosis in breast cancer cells. Loss of PHF5A suppresses cell proliferation, migration, and tumor formation.\",\n      \"method\": \"In vivo CRISPR screen, Co-IP (SF3b complex), RNA-seq, knockdown with proliferation/apoptosis phenotype readout\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen, Co-IP demonstrating SF3b stability requirement, mechanistic splicing outcome identified\",\n      \"pmids\": [\"29700004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SIRT7 decrotonylates PHF5A at K25 in senescent fibroblasts. Decrotonylation of PHF5A K25 contributes to decreased CDK2 expression through retained-intron-induced abnormal alternative splicing, thereby accelerating fibroblast senescence.\",\n      \"method\": \"Mass spectrometry crotonylome profiling, SIRT7 knockdown/overexpression, Western blot, RNA-seq splicing analysis\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification of modification site, KD/OE with defined phenotype, but single lab\",\n      \"pmids\": [\"34604215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The C. elegans ortholog of PHF5A (phf-5) is expressed in a muscle-specific, stage-specific manner (pharynx, body wall, anal muscles) during the morphogenetic phase of embryonic development. phf-5 RNAi demonstrates that PHF-5 is essential for morphogenetic development and muscle function in C. elegans embryos and young larvae.\",\n      \"method\": \"Transgenic phf-5::yfp reporter, RNAi loss-of-function, phenotypic analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization experiment tied to functional consequence via RNAi, in C. elegans ortholog\",\n      \"pmids\": [\"12359262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PHF5A (Ini) localizes to the nucleus of HeLa cells, binds to the proximal connexin43 (cx43) promoter (demonstrated by EMSA), and enhances estrogen-induced upregulation of the cx43 gene in a dose-dependent manner. PHF5A stimulates the transcriptional activating function AF-1 (but not AF-2) of estrogen receptor alpha (ERα), acting as a coactivator specific for AF-1.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), transient transfection/reporter assay, expression library screening\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — EMSA and reporter assay establish DNA binding and transcriptional coactivator function, single lab\",\n      \"pmids\": [\"12810571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In pancreatic cancer stem cells (CSCs), PAF1 interacts with PHF5A and DDX3, forming a PAF1-PHF5A-DDX3 sub-complex that binds to the promoter region of NANOG to regulate stemness. This interaction was independent of the full PAF1C complex identity.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation sequencing (ChIP-seq), DDX3 inhibitor rescue experiments\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and ChIP-seq with functional validation, single lab\",\n      \"pmids\": [\"32781084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KMT2A (a histone methyltransferase) is a physical binding partner of a PHF5A-PHF14-HMG20A-RAI1 protein subcomplex in pancreatic cancer stem cells (PCSCs) and functions as an epigenetic regulator of PCSC properties. Targeting the complex with a KMT2A-WDR5 inhibitor attenuates PCSC self-renewal capacity, cell viability, and in vivo tumorigenicity.\",\n      \"method\": \"Co-immunoprecipitation, chemical inhibitor (KMT2A-WDR5 inhibitor), in vivo tumor assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP establishes PHF5A complex membership, functional validation with inhibitor in vivo\",\n      \"pmids\": [\"37709746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PHF5A is phosphorylated at Y36 by the TrkA-ERK1/2-ABL1 signaling cascade. PHF5A is enriched in the centrosome. Phospho-Y36-PHF5A promotes interaction between CEP250 and Nek2A in a spliceosome-independent manner, leading to premature centrosome separation, which remodels microtubules and subsequently regulates cell proliferation and migration. This TrkA-ERK1/2-ABL1-PHF5A phosphorylation cascade is hyper-regulated in medulloblastoma.\",\n      \"method\": \"Phosphorylation assays, centrosome fractionation, Co-immunoprecipitation (CEP250/Nek2A), mutagenesis (Y36), kinase inhibition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical phosphorylation, Co-IP, mutagenesis and centrosome localization established, single lab\",\n      \"pmids\": [\"36759599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"De novo heterozygous PHF5A variants (including loss-of-function variants) cause a developmental syndrome with craniofacial abnormalities, developmental delay, and hypospadias. In subject-derived fibroblasts with PHF5A LOF variants, SF3B complex formation was unaffected in 2 subject cell lines, and feedback mechanisms maintain normal levels of SF3B components, suggesting disturbed autoregulation in specific cell types (e.g., neural crest cells) during embryonic development as the pathomechanism rather than simple haploinsufficiency.\",\n      \"method\": \"Clinical genomics, functional fibroblast studies, transcriptome sequencing, SF3B complex formation assays\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — subject-derived cell functional studies with SF3B complex assays and transcriptome analysis, single study\",\n      \"pmids\": [\"37422718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CHD4 promotes NSCLC proliferation and migration through its interaction with PHF5A and subsequent activation of the RhoA/ROCK signaling pathway.\",\n      \"method\": \"CHD4 knockdown/overexpression, Western blot for RhoA/ROCK markers, xenograft mouse model\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP/pulldown with pathway inference, no direct biochemical reconstitution of PHF5A's role\",\n      \"pmids\": [\"32228507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In avian neural crest (NC) development, DLC1 partners with the SF3B1-PHF5A splicing complex to determine trunk NC cell fate by regulating splicing of NC specifiers SOX9 and SNAI2 pre-mRNAs. SF3B1-PHF5A binds to intronic branch site (BS) sequences of multiple factors, while DLC1 interacts with a specific motif near the BS sequences of SOX9 and SNAI2 to confer specificity. DLC1 increases NC cell vulnerability to splicing modulator pladienolide B (PB) by reducing SF3B1-PHF5A binding capacity to weaker polypyrimidine tracts, causing intron retention.\",\n      \"method\": \"Protein-protein interaction assays, splicing reporter assays, pladienolide B pharmacology, RNA splicing analysis in avian embryos\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic binding and functional splicing studies in vivo, ortholog context (avian)\",\n      \"pmids\": [\"40691464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PHF5A silencing in esophageal squamous cell carcinoma (ESCC) promotes VEGFA ubiquitination by enhancing its interaction with the E3 ubiquitin ligase MDM2, thereby reducing VEGFA protein stability. The tumor-promoting effects of PHF5A are dependent on intact VEGFA and PI3K/AKT signaling.\",\n      \"method\": \"Co-immunoprecipitation (PHF5A-MDM2), ubiquitination assays, microarray, siRNA knockdown, xenograft\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP with ubiquitination assay, single lab, indirect link to PHF5A's canonical function\",\n      \"pmids\": [\"38429756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PHF5A regulates alternative splicing of DOCK5 to produce an oncogenic DOCK5 variant in head and neck squamous cell carcinoma (HNSCC), and this promotes HNSCC progression through p38 MAPK pathway activation.\",\n      \"method\": \"qRT-PCR, siRNA/overexpression, Western blot (p38 MAPK), xenograft, TCGA correlation\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional phenotype with pathway association, but mechanistic link between PHF5A splicing activity and p38 is indirect\",\n      \"pmids\": [\"37434235\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PHF5A is a highly conserved PHD-finger protein and core component of the SF3b subcomplex of U2 snRNP that directly contacts the branch point adenosine pocket (together with SF3B1) to regulate pre-mRNA splicing; it is subject to post-translational modifications (p300-mediated acetylation at K29, SIRT7-mediated decrotonylation at K25, and TrkA-ERK1/2-ABL1-mediated phosphorylation at Y36) that modulate its interactions with U2 snRNP components and non-canonical partners (p400, CEP250/Nek2A at centrosomes), enabling it to control alternative splicing of cancer-relevant genes, regulate RNA polymerase II elongation via the Paf1 complex in stem cells, and mediate NHEJ-dependent DNA repair through histone H2A variant deposition, with its Y36 residue also representing the binding site for clinical splicing modulator drugs.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PHF5A is a highly conserved PHD-finger protein that functions as a core subunit of the SF3b subcomplex of U2 snRNP, where it directly contacts the branch point adenosine pocket together with SF3B1 to regulate constitutive and alternative pre-mRNA splicing [PMID:28541300, PMID:23651857]. PHF5A is subject to post-translational modifications—p300-mediated acetylation at K29 strengthens U2 snRNP interactions and modulates stress-responsive splicing [PMID:31054974], SIRT7-mediated decrotonylation at K25 alters CDK2 splicing to promote senescence [PMID:34604215], and TrkA-ERK1/2-ABL1-mediated phosphorylation at Y36 drives a spliceosome-independent centrosomal function by promoting CEP250–Nek2A interaction and premature centrosome separation [PMID:36759599]. Beyond splicing, PHF5A stabilizes the Paf1 transcriptional elongation complex at pluripotency loci in embryonic stem cells [PMID:27749823] and recruits the p400 histone chaperone to immunoglobulin switch regions to deposit H2A.Z and γH2AX for NHEJ-dependent DNA double-strand break repair during class switch recombination [PMID:33938017]. De novo heterozygous PHF5A loss-of-function variants cause a developmental syndrome featuring craniofacial abnormalities, developmental delay, and hypospadias [PMID:37422718].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"The earliest functional data established that a PHF5A ortholog is essential for embryonic morphogenesis, indicating a fundamental developmental role before any molecular mechanism was known.\",\n      \"evidence\": \"C. elegans phf-5::yfp reporter and RNAi in embryos showing muscle-specific expression and lethality upon knockdown\",\n      \"pmids\": [\"12359262\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of action in muscle development unknown\", \"No link to splicing or chromatin at this stage\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"PHF5A was shown to function as a nuclear transcriptional coactivator, establishing its role in gene regulation via direct promoter binding and estrogen receptor AF-1 coactivation.\",\n      \"evidence\": \"EMSA on cx43 promoter and reporter assays in HeLa cells\",\n      \"pmids\": [\"12810571\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Coactivator function not connected to splicing machinery\", \"Single promoter target tested\", \"No structural insight into DNA-binding mode\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"PHF5A was identified as a molecular bridge linking the chromatin remodeler EP400/DDX1 to splicing factors U2AF1/SFRS5, placing it at the intersection of chromatin and splicing for the first time.\",\n      \"evidence\": \"Yeast two-hybrid, three-hybrid, Co-IP, and nuclear speckle colocalization in NIH3T3 cells\",\n      \"pmids\": [\"18758164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of bridging not tested\", \"Endogenous complex stoichiometry unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"PHF5A was demonstrated to be essential for U2 snRNP-dependent recognition of C-rich 3′ splice sites in thousands of essential genes, establishing it as a critical splicing factor with cancer-specific vulnerability in glioblastoma stem cells.\",\n      \"evidence\": \"Genome-wide RNAi screen, RNA-seq, pharmacologic U2 snRNP inhibition, in vivo xenograft in GSCs vs. normal cells\",\n      \"pmids\": [\"23651857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for C-rich splice site preference unknown\", \"Whether this selectivity is intrinsic to PHF5A or an emergent SF3b property unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"PHF5A was shown to have a splicing-independent transcriptional role: stabilizing the Paf1 complex and controlling RNA Pol II elongation at pluripotency loci, resolving how it maintains ESC self-renewal.\",\n      \"evidence\": \"Paf1 complex Co-IP, Pol II elongation assays, and differentiation phenotype upon Phf5a depletion in mouse ESCs and myoblasts\",\n      \"pmids\": [\"27749823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Paf1 stabilization is direct or via splicing of Paf1 subunit mRNAs was not fully excluded\", \"Structural basis of Paf1–PHF5A interaction unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The crystal structure of PHF5A and cryo-EM of the spliceosome revealed that PHF5A-Y36 and SF3B1 residues form the branch point adenosine-binding pocket, which is also the target of clinical splicing modulators pladienolide, herboxidiene, and spliceostatin.\",\n      \"evidence\": \"Crystal structure of human PHF5A, cryo-EM of Bact complex, Y36C mutagenesis conferring drug resistance, RNA-seq\",\n      \"pmids\": [\"28541300\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic model of drug bound in the pocket not resolved in this study\", \"Mechanism of GC-content-dependent differential sensitivity not fully explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"PHF5A was shown to be required for SF3b complex stability and to link the spliceosome to histones; its loss altered alternative splicing of apoptotic regulators including FASTK, sensitizing breast cancer cells to Fas-mediated apoptosis.\",\n      \"evidence\": \"In vivo CRISPR screen, Co-IP of SF3b complex, RNA-seq, proliferation and apoptosis assays\",\n      \"pmids\": [\"29700004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of histone linkage (direct binding vs. indirect) not structurally resolved\", \"Whether FASTK splicing change is direct or secondary unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"p300-mediated acetylation of PHF5A at K29 was identified as a stress-responsive post-translational switch that strengthens U2 snRNP assembly and globally reprograms alternative splicing, including stabilization of KDM3A mRNA in colorectal cancer.\",\n      \"evidence\": \"Acetylome MS, in vitro p300 acetylation, Co-IP of U2 snRNP components, K29 mutagenesis, RNA-seq\",\n      \"pmids\": [\"31054974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Deacetylase counteracting p300 at K29 not identified\", \"Whether K29ac and K25 crotonylation are mutually exclusive or co-regulated is unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A PAF1–PHF5A–DDX3 sub-complex was found to bind the NANOG promoter in pancreatic cancer stem cells, extending PHF5A's transcriptional role to stemness regulation independent of the canonical PAF1C.\",\n      \"evidence\": \"Reciprocal Co-IP, mass spectrometry, ChIP-seq, DDX3 inhibitor rescue in pancreatic CSCs\",\n      \"pmids\": [\"32781084\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this complex acts via chromatin remodeling or transcriptional elongation is not distinguished\", \"Generalizability beyond pancreatic CSCs untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"PHF5A was established as a DNA repair factor: it stabilizes p400 at immunoglobulin switch regions to deposit H2A.Z and γH2AX, enabling NHEJ-dependent repair of AID-induced and I-SceI-induced DSBs during class switch recombination.\",\n      \"evidence\": \"siRNA screen, ChIP for p400 and H2A variants at S regions, I-SceI DSB reporter, Co-IP\",\n      \"pmids\": [\"33938017\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PHF5A's role in DSB repair is spliceosome-dependent or independent not resolved\", \"Direct PHF5A–p400 binding interface unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"SIRT7-mediated decrotonylation of PHF5A at K25 was identified as a second acyl modification that modulates splicing, specifically causing intron retention in CDK2 mRNA to drive cellular senescence.\",\n      \"evidence\": \"Crotonylome MS, SIRT7 KD/OE, RNA-seq splicing analysis in fibroblasts\",\n      \"pmids\": [\"34604215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Crotonylation writer enzyme unknown\", \"Single-lab finding not independently confirmed\", \"Whether K25 modification affects U2 snRNP assembly as K29ac does is untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Phosphorylation of PHF5A at Y36 by TrkA-ERK1/2-ABL1 was shown to drive a spliceosome-independent centrosomal function—promoting CEP250–Nek2A interaction and premature centrosome separation—demonstrating that the same residue targeted by splicing drugs also mediates a distinct non-splicing activity relevant to medulloblastoma.\",\n      \"evidence\": \"Phosphorylation assays, centrosome fractionation, Co-IP of CEP250/Nek2A, Y36 mutagenesis, kinase inhibitors\",\n      \"pmids\": [\"36759599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study; centrosomal localization not confirmed by independent methods\", \"Whether Y36 phosphorylation and drug binding are mutually exclusive not tested\", \"Structural basis for CEP250/Nek2A interaction unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"De novo heterozygous PHF5A variants were identified as causative for a Mendelian developmental syndrome, establishing PHF5A haploinsufficiency as pathogenic in human development while revealing feedback autoregulation of SF3B complex levels.\",\n      \"evidence\": \"Clinical genomics in multiple families, fibroblast SF3B complex assays, transcriptome sequencing\",\n      \"pmids\": [\"37422718\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathogenic mechanism in neural crest cells specifically not directly demonstrated\", \"Number of affected individuals still small\", \"Genotype-phenotype correlation across variant types not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"PHF5A was placed within a PHF5A–PHF14–HMG20A–RAI1–KMT2A complex in pancreatic cancer stem cells, linking it to histone H3K4 methylation and epigenetic maintenance of stemness.\",\n      \"evidence\": \"Co-IP, KMT2A-WDR5 inhibitor, in vivo tumor assay in pancreatic CSCs\",\n      \"pmids\": [\"37709746\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PHF5A directly contacts KMT2A is unknown\", \"Stoichiometry and stability of this complex not characterized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"In avian neural crest development, DLC1 was shown to partner with SF3B1–PHF5A to confer target specificity for splicing of SOX9 and SNAI2, revealing how a non-spliceosome accessory factor co-opts the PHF5A branch-point recognition machinery to determine cell fate.\",\n      \"evidence\": \"Protein-protein interaction assays, splicing reporters, pladienolide B pharmacology, in vivo avian embryo RNA splicing analysis\",\n      \"pmids\": [\"40691464\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability to mammalian neural crest not shown\", \"Whether DLC1 interaction is conserved in human PHF5A untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: (1) how PHF5A's splicing-dependent and splicing-independent functions (Paf1 stabilization, centrosome regulation, DNA repair) are coordinately regulated; (2) the interplay among multiple acyl modifications (K29 acetylation, K25 crotonylation) and Y36 phosphorylation; and (3) the cell-type-specific pathomechanism underlying the PHF5A-associated developmental syndrome.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No integrative model of PTM cross-talk on PHF5A\", \"Tissue-specific splicing targets during embryonic development uncharacterized\", \"Full atomic structure of PHF5A within the drug-bound SF3b complex not yet available\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1, 3, 15]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 9, 10]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 9]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 1, 3, 6, 7, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 9, 10]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 13, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 6, 11]}\n    ],\n    \"complexes\": [\n      \"SF3b (U2 snRNP)\",\n      \"PAF1-PHF5A-DDX3\",\n      \"PHF5A-PHF14-HMG20A-RAI1-KMT2A\"\n    ],\n    \"partners\": [\n      \"SF3B1\",\n      \"EP400\",\n      \"U2AF1\",\n      \"PAF1\",\n      \"DDX3\",\n      \"CEP250\",\n      \"NEK2\",\n      \"DLC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}